REVB

+ Watchlist + Portfolio

Revelation Biosciences, Inc.

Regulated industry Physical products Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.80
52-Week Range: $0.76 – $6.76
Market Cap: $3.04M
P/E (TTM): 0.17
EPS (TTM): 4.60
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.30
PEG Ratio: —
Return on Equity: -154.77%
Return on Assets: -78.73%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 6.21
Debt/Equity: 0.07
Total Debt: $739.92K
Free Cash Flow: $-5.78M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $-7.70M

REVB Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$5.38M	$4.15M	$3.55M	$4.06M
Selling, General & Admin	$5.49M	$4.51M	$4.43M	$5.01M
Operating Expenses	$10.86M	$8.66M	$7.98M	$9.07M
Operating Income	-$10.86M	-$8.66M	-$7.98M	-$9.07M
EBITDA	-$10.84M	-$8.63M	-$7.95M	-$9.04M
Pretax Income	-$10.83M	-$120.25K	-$15.04M	-$8.91M
Net Income	-$10.83M	-$120.25K	-$15.04M	-$8.91M
Diluted EPS	-91775.84	-87.33	-1052.16	-23.95
Diluted Shares	118	1377	14292	620785

REVB Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$5.25M	$11.99M	$6.50M	$10.70M
Current Assets	$5.41M	$12.15M	$6.57M	$10.81M
Total Assets	$5.50M	$12.21M	$6.62M	$11.58M
Current Liabilities	$4.45M	$5.56M	$1.91M	$2.00M
Total Debt	$0.00	—	$0.00	$746.78K
Total Liabilities	$4.45M	$5.56M	$1.91M	$2.72M
Retained Earnings	-$25.35M	-$25.47M	-$40.51M	-$49.42M
Shareholders' Equity	$1.05M	$6.65M	$4.71M	$8.86M
Working Capital	$962.32K	$6.58M	$4.65M	$8.81M

REVB Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$11.22M	-$7.29M	-$18.32M	-$8.27M
Capital Expenditure	—	—	-$19.17K	—
Free Cash Flow	-$11.22M	-$7.29M	-$18.34M	-$8.27M
Depreciation & Amortisation	$25.05K	$25.05K	$27.92K	$27.06K
Stock-Based Compensation	$301.12K	$155.72K	$168.85K	$595.37K
Investing Cash Flow	$0.00	$0.00	-$19.17K	$0.00
Financing Cash Flow	$15.20M	$14.03M	$12.85M	$12.47M
Share Repurchases	—	-$5.00K	$0.00	—
Net Change in Cash	$3.98M	$6.74M	-$5.49M	$4.20M

REVB Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$858.83K	$1.32M	$922.86K	$964.19K	$1.38M	$1.92M
Selling, General & Admin	$1.24M	$1.14M	$1.02M	$1.61M	$1.72M	$1.74M
Operating Expenses	$2.09M	$2.46M	$1.94M	$2.57M	$3.09M	$3.66M
Operating Income	-$2.09M	-$2.46M	-$1.94M	-$2.57M	-$3.09M	-$3.66M
EBITDA	-$2.09M	-$2.45M	-$1.94M	-$2.57M	-$3.09M	-$3.65M
Pretax Income	-$2.05M	-$2.44M	-$1.91M	-$2.51M	-$3.01M	-$3.32M
Net Income	-$2.05M	-$2.44M	-$1.91M	-$2.51M	-$3.01M	-$3.32M
Diluted EPS	-25.32	-28.04	-7.08	-1.65	-2.71	-0.87
Diluted Shares	80942	200668	661183	1.52M	3.21M	3.83M

REVB Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$3.70M	$5.17M	$12.71M	$10.70M	$14.11M	$11.48M
Current Assets	$3.93M	$5.36M	$12.83M	$10.81M	$14.21M	$11.68M
Total Assets	$3.97M	$5.40M	$12.86M	$11.58M	$15.04M	$12.50M
Current Liabilities	$1.09M	$1.57M	$1.85M	$2.00M	$1.42M	$1.88M
Total Debt	—	—	—	$746.78K	$759.04K	$739.92K
Total Liabilities	$1.09M	$1.57M	$1.85M	$2.72M	$2.06M	$2.43M
Retained Earnings	-$42.56M	-$45.00M	-$46.91M	-$49.42M	-$52.43M	-$55.75M
Shareholders' Equity	$2.88M	$3.83M	$11.00M	$8.86M	$12.99M	$10.07M
Working Capital	$2.84M	$3.79M	$10.98M	$8.81M	$12.79M	$9.80M

REVB Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$2.79M	-$1.92M	-$1.59M	-$1.97M	-$3.21M	-$2.56M
Capital Expenditure	—	—	—	—	-$71.88K	-$39.63K
Free Cash Flow	-$2.79M	-$1.92M	-$1.59M	-$1.97M	-$3.29M	-$2.60M
Depreciation & Amortisation	$7.22K	$7.22K	$6.76K	$5.85K	$7.20K	$8.31K
Stock-Based Compensation	$223.46K	$873.00	$874.00	$370.17K	$471.00K	$401.42K
Investing Cash Flow	$0.00	$0.00	$0.00	$0.00	-$71.88K	-$39.63K
Financing Cash Flow	$0.00	$3.39M	$9.12M	-$41.17K	$6.70M	-$33.80K
Net Change in Cash	-$2.79M	$1.47M	$7.53M	-$2.01M	$3.41M	-$2.63M

Market Snapshot

About

Revelation Biosciences is a clinical-stage biotechnology company developing therapies that modulate the innate immune system. The company focuses on treatments for allergic and inflammatory diseases, with candidates targeting conditions like allergic conjunctivitis and atopic dermatitis. Revelation aims to provide alternatives to traditional immunosuppressive therapies.